Paper presented on July 10, 1952. See, for example, the exhaustive review by Bltchie, P. D., “Advances in Enzymol.”, 7, 65 (1947). Henderson, G. M., and Rule, H ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study,” published in the January 2025 issue ...

The company’s lead drug candidate utilizing WaferiX is Wafermine, the world’s first patented sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain and major ...

Levocloperastine is a novel antitussive with a pharmacological profile distinct from that of the racemic DL-cloperastine. Levocloperastine with its dual mechanism of action acts on both the ...

The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the CNS resulting from its ...